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Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies
involving joints. To date, TNFα-blocking agents administration is the most promising
therapy, although these treatments are associated with an increased Polyomavirus
JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal
Leukoencephalopathy (PML). The aim of this study was the recruitment and the
analysis of a CIRDs cohort in order to investigate a possible correlation between
JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine
samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0)
and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC
viruria significantly higher than JC viremia throughout the 18 month follow-up study
(p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was
analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the
exception of a sequence isolated from a plasma sample, that corresponds to the type
II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed
and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since
only few studies have been carried out to understand whether there is a PML risk in
CIRDs population infected by JCPyV, this study contributes to enrich literature insight on
JCPyV biology in this cluster. Further investigations are necessary in order to recognize
the real impact of biologics on JCPyV life cycle and to identify possible and specific viral
variants related to increased virulence in CIRDs patients.
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INTRODUCTION
Chronic Inflammatory Rheumatic Diseases (CIRDs) are severe
and chronic pathologies that cause deterioration of the quality of
life and place a major burden on health care systems worldwide
(Mócsai et al., 2014).
Rheumatic Arthritis (RA) is a multiple joints inflammatory
disease associated with an increased mortality when
autoantibodies can be detected in the serum (Gerlag et al., 2015;
Lahiri and Dixon, 2015). Its prevalence rate is approximately
1%, peaking between the ages of 35 and 50 years (Kelly,
2015).
Ankylosing spondylitis (AS) is a chronic inflammatory disease
that affects 1% of the general population. Pathogenesis causes
destruction and fusion of the spinal vertebrae and sacroiliac
joints and the ligament calcification process, which results in pain
(Ghasemi-Rad et al., 2015).
Psoriatic arthritis (PsA) is a systemic inflammatory arthritis
characterized by chronic and progressive disease leading to lost
productivity and reduced quality of life. PsA affects men and
women equally (Dewing, 2015). PsA is a distinct disease respect
to RA and AS, nevertheless, disease-modifying anti-rheumatic
drugs (DMARDs) were introduced into the therapy of all
these inflammatory rheumatic diseases to provide symptomatic
improvement and to progress or maintain quality of life (Moll
and Wright, 1973; Bijlsma, 2012). Methotrexate (MTX) is the
DMARD most widely used and it remains the first line therapy
nevertheless its cytotoxic nature and/or partial efficacy limit its
use (Mócsai et al., 2014).
Pro-inflammatory cytokines are also involved in the
pathogenesis of many inflammatory and autoimmune diseases
since their overexpression. Therefore, to counteract this
phenomenon, synthetic glucocorticoids (GCs) are widely used,
unfortunately, many patients show unresponsiveness called GC
resistance (GCR) (Dejager et al., 2014).
Therapeutics molecules of biologic origin are named biologic
agents, among them, drugs that block tumor necrosis factor alpha
(TNF-α) were introduced into the therapy of autoimmune and
inflammatory diseases in the late 1990s (Mócsai et al., 2014).
Unfortunately, treatments with biologicals are increasingly
associated with amplified susceptibility to viral infections, in
particular, new studies are performed to understand the role
of Polyomavirus John Cunningham (JCPyV) in development
of a demyelinating disease, named Progressive Multifocal
Leukoencephalopathy (PML), in patients treated with anti-TNF
α (Comar et al., 2013). PML occurs as a consequence of lytic
infection of oligodendrocytes with a tumultuous disease course
and poor prognosis within a few months. It is still unclear
whether the virus seeds into the Central Nervous System (CNS)
during primary viremia or following latency escape (secondary
viremia), in fact, whether JCPyV is carried into the brain by
infected lymphocyte or whether it directly crosses the brain
barrier, is a matter of debate (Hirsch et al., 2013). JCPyV is a
non-enveloped icosahedron constituted by three viral proteins
(VP1-3) with VP1 being the major constituent and determines
receptor specificity and viral genotypes (Agostini et al., 2001;
Ferenczy et al., 2012).
There are several distinct PML risk populations. The largest
is the human immunodeficiency virus positive PML population.
the second one is represented by patients with various forms
of hematological malignancies and at present, the third-largest
risk population is relapsing–remitting multiple sclerosis patients
treated with natalizumab. Anti-JCV antibody positive patients
are the main at risk and present a survival rate of 77% based
on 517 PML patients with average follow up of almost 3 years
after PML diagnosis. However, 40% of survivors had severe
disability, 47% had moderate disability and 13% had mild
disability (Pavlovic et al., 2015).
Because of the low PML incidence reported in patients with
RA, the potential positive predictive value of the anti-JCV assay
would be too low to serve as a valuable risk-mitigation option.
If patients with RA are risk stratified assuming an anti-JCV
antibody seropositivity of 60%, theoretically 23,400 anti-JCV
antibody-positive patients would have to receive rituximab before
potentially observing 1 PML case. Cases of rituximab-associated
PML have often been characterized by underlying diagnoses and
prior immunosuppressant use (Borie and Kremer, 2015).
Poor data are present in literature regarding the possible
link between administration of etanercept and JCV infection
or reactivation in treated patients. However, in 2012, Nardis
et al., found JCV DNA in 2/15 PsA patients and in the same
year, in a 23-year-old Native American woman with a history of
systemic lupus erythematosus and erosive polyarthritis treated
with prednisone and etanercept, PML was diagnosed (Graff-
Radford et al., 2012; Nardis et al., 2012).
Infliximab is used for the treatment of Crohn’s disease (CD),
severe forms of plaque psoriasis, RA and spondyloarthritis hence,
its association with JCV infection/reactivation in treated patients
is largely studied. In an observational study published in 2013 by
Bellizzi et al., JCV DNA was found in biological samples of either
CIRDs and CD patients treated with this medication. In 2 CD
subjects a rearranged form of the viral non-coding control region
(NCCR) was also found in colon-rectal biopsies after 16 months
of therapy (Bellizzi et al., 2013a).
NCCR is hyper-variable, contains a promoter/enhancer
arrangement responsible for neurotropism and neuro-virulence
affecting viral transcription and replication (Ferenczy et al.,
2012). Four distinct structural forms of NCCR (I-S, I-R, II-S, and
II-R) are defined along with tissue tropisms: type II-S is identified
as archetype CY and it is composed of six boxes named A-F.
Each box contains binding sites for transcriptional cell factors
involved in viral transcription. These binding sites undergo to
deletion and enhancement process generating variants that could
up-modulate viral expression in a specific anatomical site and
could alter the cellular host range (Jensen and Major, 2001; Tan
and Koralnik, 2010). Type I-S is 98 bp long and it is composed
of boxes A, C and E. Type I-R has repeats of this 98 bp unit,
with various deletions, as seen in the JCPyV prototypeMad-1 and
Mad-4 strains; both of these types have no boxes B and D (Jensen
and Major, 2001; Tan and Koralnik, 2010). Mad-1 strain was
isolated from tissues of PML patients (Jensen and Major, 2001;
Tan and Koralnik, 2010) and it was named on the hypothesis that
it results from a rearrangement of the archetype (Marshall and
Major, 2010).
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Finally, type II-R is composed by rearranged NCCRs
characterized by repeats of the 98 bp unit with inserts and
various mutations (Jensen and Major, 2001; Tan and Koralnik,
2010). Rearranged NCCRs can correlate with PML poor clinical
outcome (Marshall and Major, 2010).
Although viral infection and replication occurs at very high
incidence, as demonstrated by Egli et al., on 400 consecutive
blood donors (Egli et al., 2009), PML is a rare disease,
nevertheless, its onset as a side effect of immune-modulatory
therapy, is a growing concern with reports of fatal cases (Molloy
and Calabrese, 2012; Bellizzi et al., 2013b). Therefore, continued
research and a more detailed understanding of JCPyV biology,
epidemiology and pathology are of increasing importance.
On these bases, the objective of this study was to recruit and
to analyze a cohort of subjects affected by CIRDs, including RA,
AS and PsA, in order to evaluate JCPyV circulation in CIRDs
patients and the possible influence of anti-TNF-α agents on
viral loads. In addition, in JCPyV positive samples, NCCR was
analyzed to perceive whether particular rearrangements could
have arisen in a specific CIRD. Finally, in order to identify
the most prevalent JCPyV genotype in CIRDs cohort, VP1
genotyping was performed.
MATERIALS AND METHODS
Patients and Samples
In this study, 34 subjects affected by CIRDs (12males, 22 females)
were dynamically enrolled. Patient’s mean age ± standard
deviation (std. dev.) was 52 ± 12 years (range: 25–74 years) and
the mean disease duration was 115.4 ± 116.1 months (range:
9–480 months). Among these 34 outpatients, 8 were affected
by RA (8 females), 8 were affected by AS (4 males, 4 females)
and 18 patients were affected by PsA (10 males, 8 females). This
cohort, referred to the Department of Internal Medicine and
Medical Disciplines, Rheumatology Unit (Sapienza University of
Rome, Italy), was composed by subjects enrolled from January
2013 to May 2015. Patients were treated first with DMARDs
and/or GCs and successively with anti-TNF-α (golimumab,
adalimumab, etanercept, certolizumab pegol), DMARDs and/or
GCs when they resulted unresponsiveness exclusively to
DMARDs therapy. After obtaining informed consent, basic
demographic data including concomitant medications and
disease activity measures, were collected and recorded on a
standardized form, just before the beginning of biologic therapy.
All patients were classified according to standard criteria (Van
der Linden et al., 1984; Arnett et al., 1988; Taylor et al., 2006),
designated to start biologic treatment and consecutively enrolled.
Each patient was evaluated by the same rheumatologist. RA and
PsA clinical evaluation included: swollen (SJC) and tender joint
count (TJC), patient and physician global assessment on a visual
analog scale (VAS, 0–100 mm), and HAQ (Fries et al., 1982). The
HAQ scores range from 0 to 3, with a higher score indicating a
higher level of disability (Lesuis et al., 2012). A blood drawing was
also performed to evaluate ESR (mm/h) and CRP (mg/l). Disease
activity was assessed by the DAS28-CRP and/or the DAS28-
ESR, with a high score indicating more active disease (Lesuis
et al., 2012). Current disease activity in patients with AS was
measured by the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI), ranging from 0 (no activity) to 10 (maximum
activity) (Garrett et al., 1994) (Tables 1, 2).
From each of these 34 outpatients, a sample of urine, plasma
and peripheral blood mononuclear cells (PBMCs) was collected
prior anti-TNF-α agents treatment (baseline designated as t0)
and during the follow-up at 3 (T3), 6 (T6), 12 (T12), and 18
months (T18) after starting biological therapy. In particular, 33
urine and blood samples were collected from 33 patients at T3, 31
urine and 32 blood samples were collected from 32 patients at T6,
31 urine and 32 blood samples were collected from 32 patients at
T12 and finally 32 urine and blood samples were collected from
32 patients at T18.
Clinical Specimens Processing and JCV
DNA Extraction
DNA for molecular analysis was extracted from 500 µl of
each urine, collected without preservatives, using the DNeasy R©
Blood & Tissue Kit (QIAGEN, S.p.A, Italy) according to the
manufacturer’s instructions. Blood samples, collected in 4-mL
Vacutainer R© tubes containing EDTA (BD Becton Dickinson
S.p.A, Italia), were centrifuged at 1.376 g/s for 10 min and
DNA was extracted from 200 µL of plasma using the DNeasy R©
Blood & Tissue Kit (QIAGEN, S.p.A, Milan, Italy). PBMCs were
isolated from whole blood using the standard Ficoll Hypaque
density gradient centrifugation technique (Bøyum et al., 1991),
and the number of viable leukocytes was determined by trypan
blue exclusion. PBMCs DNA extraction was performed on 106
cells by the QIAmp R© DNA Blood Kit (QIAGEN S.p.A, Milan,
Italy) according to the manufacturer’s instruction. DNA yield
of all biological specimens was determined by measuring its
concentration in the eluate by absorbance at 260 nm and then
stored at−20◦C until use.
Standard laboratory procedures for sterile DNA extraction
and PCR were practiced for all specimens.
Quantitative PCR (Q-Pcr) for JCPyV TAg
DNA extracted from each sample was tested for JCV genome
detection and quantification by Q-PCR following a published
protocol (Delbue et al., 2008). Each sample was analyzed in
duplicate and the viral loads were given as the mean of at
least two positive reactions. Standard precautions designed to
prevent contamination were followed and a negative control was
included in each run. Viral DNA was quantified using a standard
curve consisted of serial dilutions at known titer of a plasmid
containing the entire JCPyV genome. For urine and plasma,
viral DNA was expressed as genome equivalents (gEq)/ml and as
genome equivalents (gEq)/106 cells for PBMCs.
PCR for JCPyV NCCR
In order to amplify the JCPyV NCCR, a nested-PCR employed
two pairs of primers that anneal to the invariant regions flanking
JCPyV NCCR was performed (Pietropaolo et al., 2003). The
first pair primers amplified a 724 bp DNA fragment in JCPyV
(Mad-1) whereas the second pair annealed to a portion of
the first round PCR product, generating a fragment of 308
bp (Flaegstad et al., 1991; Markowitz et al., 1993). Standard
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TABLE 1 | Clinical data of patients affected by CIRDs at baseline and during follow-up.
Parameters T0 T3 T6 T12 T18 p-value§
M/F (n) n patients 12/22 34 12/21 33 11/21 32 10/22 32 11/21 32
Age◦ (median/range) 52/25–74
Diagnosis: PsA/AR/AS 18/8/8 17/8/8 17/8/7 17/8/7 16/8/8
Months of disease (median/range) 66/9–480
CRP (mg/dl; median/25th-75th percentile) 0.22/0.08–0.75 0.19/0.08–0.53 0.15/0.09–0.49 0.23/0.14–0.77 0.31/0.16–0.56 0.416
ESR (mm/h; median/25th–75th percentile) 14/8–25 13/6–20 14/7–19 11/5–21 16/6–19.3 0.580
HAQ (0–3; mean/SD) 0.92 ± 0.72 0.80 ± 0.75 0.73 ± 0.72 0.70 ± 0.66 0.64 ± 0.66 0.498
DAS28-ESR (mean/SD)* 3.74 ± 0.97 2.69 ± 1.10 2.70 ± 0.82 2.81 ± 0.62 3.49 ± 1.08 0.002
DAS28-CRP (mean/SD)* 3.24 ± 0.85 2.60 ± 1.10 2.56 ± 0.75 2.76 ± 0.84 3.18 ± 1.27 0.085
Physician’s global assessment of disease activity
(0–100 mm, VAS; mean/SD)*
46.1 ± 19.1 26.18 ± 23.12 23.88 ± 22.61 27.03 ± 23.45 26.38 ± 20.67 <0.0001
Patient’s global assessment of disease activity
(0–100 mm, VAS; mean/SD)*
55.2 ± 26.6 40.15 ± 24.82 35.63 ± 25.78 34.72 ± 23.45 35.28 ± 27.83 0.007
BASDAI (1–10; mean/SD)** 5.61 ± 2.92 4.12 ± 2.82 4.58 ± 3.80 3.95 ± 2.97 4.15 ± 2.90 0.305
BIOLOGIC AGENTS USED FOR CIRDS TREATMENT
golimumab (n/%) 10/29.4 10/30.3 10/31.3 10/31.3 10/31.3
Adalimumab (n/%) 11/32.4 11/33.3 9/28.1 10/31.3 10/31.3
Etanercept (n/%) 11/32.4 10/30.3 11/34.4 10/31.3 10/31.3
Certolizumab pegol (n/%) 2/5.9 2/6.1 2/6.3 2/6.3 2/6.3
Concomitant DMARDs (n/%) 10/29.4 8/24.2 8/25 7/21.9 6/18.8
Concomitant DMARDs and glucocorticoids (n/%) 7/20.6 6/18.2 7/21.9 5/15.6 4/12.5
Concomitant glucocorticoids (n/%) 9/26.5 3/9.1 4/12.5 4/12.5 8/25
No concomitant treatment (n/%) 4/11.8 15/45.5 10/31.5 11/34.4 12/37.5
Other concomitant treatments (n/%) 4/11.8 1/3.0 3/9.4 5/15.6 2/6.3
PsA, psoriatic arthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire;
SD, standard deviation; DAS28, 28-joint Disease Activity Score; VAS, visual analog scale; BASDAI, Bath Ankylosing Spondylitis Diseease Activity Index; DMARDs, disease modifying
anti-rheumatic drugs. *For patients with RA and PsA. **For patients with AS and PsA. ◦Age: expressed in years. §By Kruskal-Wallis test. p < 0.05 was considered statistically significant.
Bold values are statistically significant.
precautions designed to prevent contamination were followed
and a negative control was included in each run (Kwok and
Higuchi, 1989).
PCR products were detected by electrophoresis on a ethidium
bromide-stained 2% agarose gel and visualized under UV
light.
PCR for JCPyV VP1
In order to define the JCPyV genotype of the isolated viral strains,
a 215-bp fragment of the JCPyV VP1 gene was amplified using a
single set of primers (Agostini et al., 2001).
PCR products were detected by electrophoresis on a 2%
agarose gel stained with ethidium bromide and visualized under
UV light.
Sequencing of JCPyV NCCR and VP1
Regions
PCR products corresponding to JCPyV NCCR and VP1 regions
were purified prior to sequencing (Pietropaolo et al., 2003).
DNA sequencing was performed in service (BioFab research s.r.l.,
Rome, Italy). All sequences obtained fromNCCR amplicons were
compared to JCPyV NCCR of the prototype Mad-1 (GenBank:
J02227) and of the archetype CY (GenBank: AB038249.1).
Sequences corresponding to VP1 amplicons, were classified into
the known genotypes/subtypes according to the single nucleotide
polymorphisms (SNPs) patterns and aligned with those reported
by Jobes et al. (2001). Sequence alignments were performed with
ClustalW2 at the EMBL-EBI website using default parameters
(ClustalW2 - multiple sequence alignment1).
Cloning and Sequencing
PCR amplicons corresponding to the exact size of JCPyV NCCR,
were cloned into a pGEM-T Easy Vector (Promega Corporation,
Madison, WI). Plasmid DNA was purified from up to 25
clones of amplicons, visualized in 1% agarose gel electrophoresis
and sequenced (BioFab research s.r.l., Rome, Italy). Homology
between obtained sequences and/or the prototype Mad-1 and
the archetype CY was searched by ClustalW2 at the EMBL-EBI
website (ClustalW2 - multiple sequence alignment).
Data Analysis
Data were summarized as medians and ranges or as mean ±
standard deviation, as appropriate. If Z-test indicated a non-
normal distribution, we used non-parametric tests such as
Mann–Whitney U-test and Kruskal–Wallis test. Categorical data
were analyzed by using χ2-test and Student’s t-test. P< 0.05 were
considered statistically significant.
1ClustalW2 - multiple sequence alignment http://www.clustal.org/clustal2
Frontiers in Microbiology | www.frontiersin.org 4 May 2016 | Volume 7 | Article 672
Rodio et al. JC Viruria in CIRDs Patients
TABLE 2 | Clinical data of patients affected by RA, AS and PsA at baseline (T0).
Diagnosis PsA RA AS p-value§
Total 18 8 8
M/F (n) 8/10 0/8 4/4
Age◦ (median/range) 51.5/38–72 64/40–74 41/25–59
Months of disease (median/range) 72/24–480 96/24–360 48/9–168
CRP (mg/dl; median/25th–75th percentile) 0.20/0.08–0.44 0.5/0.05–0.95 0.80/0.44–2.86 0.087
ESR (mm/h; median/25th–75th percentile) 13.5/8.8–20.8 20.5/13.3–39 9.0/7.0–28.5 0.506
HAQ (0-3; mean/SD) 0.87 ± 0.73 1.28 ± 0.89 0.80 ± 0.57 0.344
DAS28-ESR (mean/SD)* 3.60 ± 0.97 4.27 ± 1.01 / 0.193
DAS28-CRP (mean/SD)* 3.20 ± 0.85 3.60 ± 1.00 / 0.350
Physician’s global assessment of disease activity (0–100 mm, VAS; mean/SD)* 43.72 ± 21.28 44.75 ± 19.65 53.88 ± 12.06 0.147
Patient’s global assessment of disease activity (0–100 mm, VAS; mean/SD)* 49.67 ± 27.08 60.75 ± 27.20 64.25 ± 24.42 0.348
BASDAI (1–10; mean/SD)** 5.39 ± 2.48 / 6.23 ± 3.66 0.624
Biologic agents used for treatment
Golimumab (n/%) 5/27.8 / 5/62.5
Adalimumab (n/%) 5/27.8 3/37.5 3/37.5
Etanercept (n/%) 8/44.4 3/37.5 /
Certolizumab pegol (n/%) / 2/25 /
Concomitant DMARDs (n/%) 5/27.8 4/50 1/12.5
Concomitant DMARDs and glucocorticoids (n/%) 3/16.7 3/37.5 1/12.5
Concomitant glucocorticoids (n/%) 6/33.3 1/12.5 2/25
No concomitant treatment (n/%) 3/16.7 / 1/12.5
Other concomitant treatments (n/%) 1/5.6 / 3/37.5
PsA, psoriatic arthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire;
SD, standard deviation; DAS28, 28-joint Disease Activity Score; VAS, visual analog scale; BASDAI, Bath Ankylosing Spondylitis Diseease Activity Index; DMARDs, disease modifying
anti-rheumatic drugs. *For patients with RA and PsA. **For patients with AS and PsA. ◦Age: expressed in years. §By Kruskal-Wallis test or by Mann–Whitney U-test. p < 0.05 was
considered statistically significant.
RESULTS
Follow-Up of JC Viral Load in Urine,
Plasma and PBMCs Samples Collected
from CIRDs Patients
In this study, 34 subjects affected by CIRDs (12males, 22 females)
were dynamically enrolled. These outpatients were divided in
three different classes on the basis of their pathology: 8 RA (8
females), 8 AS (4 males, 4 females) and 18 PsA (8 males, 10
females). Patients demographic and clinical characteristics are
shown inTables 1, 2. None of the patients developed neurological
symptoms suggestive of PML at any time point of this 18 month
follow-up study.
At baseline, 34 urine were screened for the presence of
JCPyV DNA. Q-PCR revealed that 16/34 (47.1%) urine were
JCPyV-positive with a median value of 6.73 log10 (gEq)/ml
(range: 4.23–8.10) (Tables 3, 4). The median values of each class
are reported in Tables 3, 4. Regarding the 34 plasma samples
collected at baseline, 4/34 (11.8%) patients (1 RA, 1 AS and 2
PsA) were found positive to JCPyV DNA with a median value
of 4.62 log10 (gEq)/ml (range: 4.51–4.74) (Tables 3, 4). The
median values of each class are shown in Table 4. Moreover,
3 out of these 4 patients showed also JC viruria (Figure 1).
Finally, PBMCs samples were all negative for JCV DNA
(Tables 3, 4).
Three months after starting anti-TNF-α treatment (T3), 33
urine samples, 33 plasma and 33 PBMCs were collected (8 AR,
8 AS, and 17 PsA). Viral DNA was found in 13/33 (39.4%) urine
with a median value of 5.10 log10 (gEq)/ml (range: 4.83–5.28)
(Tables 3, 4). The median values of RA, AS and PsA groups
are described in Table 4. About plasma, JCPyV was found in
5/33 (15.2%) samples (1 RA and 4 PsA) with a median value
of 4.83 log10 (gEq)/ml (range: 4.41–5.28) (Tables 3, 4). The
median values calculated for PsA and RA groups both are shown
in Table 4. JCPyV was not revealed in AS patients (Table 4).
Among the 5 patients with viremia, 3 were also JCV-positive in
urine samples (Figure 1). Regarding PBMCs, 3 out of 33 (9.1%)
patients (1 RA, 1 AS, and 1 PsA) resulted positive for JCPyVDNA
with a median value of 3.38 log10 (gEq)/106cells (Tables 3, 4).
At T6, corresponding to 6 months of anti-TNF-α treatment,
31 urine samples, 32 plasma and 32 PBMCs were collected from
32 patients (8 AR, 7 AS, and 17 PsA). At this time point, 14/31
(45.2%) urine were found JCPyV positive with a median value of
6.05 log10 (gEq)/ml (range: 3.20–7.61) (Tables 3, 4). The median
values of each class are reported in Table 4.
Regarding plasma, 3/32 (9.4%) samples (1 RA, 1 AS, and
1PsA) were found positive to viral genome with a median
value of 3.87 log10 (gEq)/ml (range: 3.45–5.20) (Tables 3, 4).
The median values of the three studied classes are labeled in
Table 4. 2 out of the 3 patients showed also viruria (Figure 1).
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TABLE 3 | JC viral load in biological specimens collected from patients with Chronic Inflammatory Rheumatic Diseases at baseline and during the
follow-up.
Pt (n)a Pt JCPyV Pt JCPyV Urine Plasma PBMCs p-valuee
+ (n)b − (n)b
JCPyV+/JCPyV log10 gEq/mL JCPyV+/JCPyV log10 gEq/mL JCPyV+/JCPyV log10 gEq/106c
−(NA)c (range)d − (NA) (range)d − (NA) (range)d
T0 34 17 17 16 ÷ 18 6.73 (4.23–8.10) 4 ÷ 30 4.62 (4.51–4.74) 0 ÷ 34 / 0.011
T3 33 (1) 16 17 13 ÷ 20 (1) 6.41 (3.74–8.04) 5 ÷ 28 (1) 4.83 (4.41–5.28) 3 ÷ 30 (1) 3.38 (2.81–3.76) 0.183
T6 32 (2) 15 17 14 ÷ 17 (3) 6.05 (3.20–7.61) 3 ÷ 29 (2) 3.87 (3.45–5.20) 0 ÷ 32 (2) / 0.059
T12 32 (2) 11 21 13 ÷ 18 (3) 6.24 (2.87–8.80) 1 ÷ 31 (2) 3.86 2 ÷ 30 (2) 3.37 (3.39–3.35) 0.321
T18 32 (2) 27 5 25 ÷ 7 (2) 4.99 (2.55–8.29) 12 ÷ 20 (2) 4.05 (3.83–4.98) 21 ÷ 11 (2) 3.10 (2.06–3.77) 0.098
p-valuee 0.121 0.045 0.603
RR 2.08
(IC 95%) (1.70–2.55)
p-valuef 0.00001
aPt, patients; n, number of patients.
bPt JCPyV+ and Pt JCPyV−, number of patients with or without JCPyV DNA in at least 1 sample of plasma and/or PBMCs and/or urine.
cNA, sample not available.
dJCV loads values were expressed as median (range) of log10 genome equivalent (gEq)/mL in urine and in plasma, and as median (range) log10 gEq/106 cells in PBMCs (gEq/106 c).
eBy Mann–Whitney U-test and by Kruskal-Wallis test. p < 0.05 was considered statistically significant.
fRelative risk (RR) and 95% confidence interval (95% CI) statistically significant with a p < 0.05 by χ2-test.
Finally, no JCPyV DNA was detected in PBMCs specimens
(Tables 3, 4).
After 1 year of anti-TNF-α treatment (T12), 32 patients (8
AR, 7 SA, and 17 PsA) were screened for JCPyV DNA. JCPyV
viruria was found in 13 out of 31 (41.9%) specimens with a
median value of 6.24 log10 (gEq)/ml (range: 2.87–8.80) (Tables 3,
4). The median values calculated for the three groups are shown
in Table 4. Conversely, JCPyV viremia was detected in a single
patient affected by PsA, with a viral load of 3.86 log10 (gEq)/ml
(Tables 3, 4 and Figure 1). Regarding PBMCs samples, JCPyV
DNA was found in two patients: one affected by AS, with a viral
load value of 3.35 log10 (gEq)/ml, and the other one affected by
PsA, showing a viral load of 3.39 log10 (gEq)/ml (Tables 3, 4).
Both patients were also JCPyV-positive in urine samples (data not
showed).
Finally, 32 urine and blood specimens, belonging to 8 AR, 8
SA, and 16 PsA, were collected 18 months after starting biologics
(T18). At this time point of follow-up, JCPyV viruria was detected
in 25/32 (78.1%) CIRDs patients with a median load value of
4.99 log10 (gEq)/ml (range: 2.55–8.29) (Tables 3, 4). The median
values of each class are reported in Table 4. Concerning viremia,
JCPyV DNA was revealed in 12 out of 32 (37.5%) CIRDs patients
screened, with a median load value of 4.05 log10 (gEq)/ml (range:
3.83–4.98) (Tables 3, 4). Moreover, Table 4 showed the median
values of RA, AS and PsA classes. Interestingly, all viremic
patients showed viruria, with the exception of a single subject
affected by PsA (Figure 1). Finally, 21/32 (65.6%) PBMC samples
resulted JCPyV-positive with a median viral load of 3.10 log10
(gEq)/ml (range: 2.06–3.77) (Table 2). In particular, 6 out of these
21 PBMC samples were isolated from patients with RA, 5 from
patients with AS and 10 from patients with PsA. The median
JCPyV load values found are reported in Table 4. Among 21
patients with JCV-positive PBMCs, 8 showed viruria and one
patient was also viremic (data not shown).
It is noteworthy that, comparing the values of JC viruria and
viremia obtained from CIRDs patients throughout the follow-up,
the mean values of JC viruria were always higher than that of JC
viremia (p = 0.002) (Figure 2). In addition, a relative risk (RR)
of viral reactivation with urinary shedding equal to 2.08 (95% CI
1.70–2.55) was estimated (Table 3). Therefore, JCPyV shedding
in the urine is favored respect to JCPyV circulation in the blood
compartment where the virus is detected at very low incidence.
However, neither the age of patients nor the administration of
biologics alone nor the co-administration of DMARDs and/or
GCs was different between JCPyV-positive and JCPyV-negative
patients in urine (data not shown).
PCR and Sequencing Analysis of JCPyV
NCCR and VP1 Regions
JCPyV NCCR was searched in all Q-PCR specimens resulted
positive to viral DNA. Successively, correct size amplicons were
cloned, and up to 25 clones for each PCR product were sequenced
to identify NCCR variants. As previously described, four distinct
structural forms of JCPyV NCCR (I-S, I-R, II-S, and II-R) have
been identified (Jensen and Major, 2001; Figure 3A). Results
showed that all sequences belonged to type II-S (archetype CY),
with the exception of a sequence isolated from a plasma sample
characterized by the subsequent structure: the entire box A is
directly followed by a complete box C because of the whole box B
was deleted, then a rearranged box Cwas present and it was tailed
by shortened sequence of boxes D and E. A new duplication of
box C (complete and rearranged) and of incomplete boxes D and
E followed by the entire box F were observed (Figure 3B).
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TABLE 4 | JC viral load in biological samples collected from patients with psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis at baseline
and during the follow-up.
Sampling time CIRDs PsA RA AS p-value
T0* Plasma JCPyV+/JCPyV− 4 ÷ 30 2 ÷ 16 1 ÷ 7 1 ÷ 7 0.079
Plasma log10 JCPyV load (range)§ 4.62 (4.51–4.74) 4.57 (4.51−4.62) 4.74 4.62
25th–75th percentile 4.59–4.65 / / /
Urine JCPyV+/JCPyV− 16 ÷ 18 7 ÷ 11 5 ÷ 3 4 ÷ 4
Urine log10 JCPyV load (range)§ 6.73 (4.23–8.10) 6.48 (4.23–8.09) 5.11 (4.69–6.89) 7.74 (6.58–8.10)
25th–75th percentile 5.42–7.51 5.99–7.31 5.07–6.88 7.41–7.88
PBMCs JCPyV+/JCPyV− 0 ÷ 34 0 ÷ 34 0 ÷ 34 0 ÷ 34
PBMCs log10 JCPyV load (range)§ / / / /
T3* Plasma JCPyV+/JCPyV− 5 ÷ 28 (1NA) 4 ÷ 13 (1NA) 1 ÷ 7 0 ÷ 8 0.942
Plasma log10 JCPyV load (range)§ 4.83 (4.41–5.28) 4.75 (4.41–5.28) 5.10 /
25th–75th percentile 4.66–5.10 4.60–4.94 / /
Urine JCPyV+/JCPyV− 13 ÷ 20 (1NA) 4÷13 (1NA) 4 ÷ 4 5 ÷ 3
Urine log10 JCPyV load (range)§ 6.41 (3.74–8.04) 6.62 (4.23–7.43) 6.27 (4.44–7.30) 5.50 (3.74–8.04)
25th–75th percentile 4.44–7.30 5.87–6.97 5.60–6.74 3.76–8.01
PBMCs JCPyV+/JCPyV− 3 ÷ 30 (1NA) 1 ÷ 16 (1NA) 1 ÷ 7 1 ÷ 7
PBMCs log10 JCPyV load (range)§ 3.38 (2.81–3.76) 2.81 3.38 3.76
25th–75th percentile 3.10–3.57 / / /
T6* Plasma JCPyV+/JCPyV− 3 ÷ 29 (2NA) 1 ÷ 16 (1NA) 1÷7 1÷6 (1NA) 0.424
Plasma log10 JCPyV load (range)§ 3.87 (3.45–5.20) 3.45 5.20 3.87
25th–75th percentile 3.66–4.54 / / /
Urine JCPyV+/JCPyV− 14 ÷ 17 (3NA) 6 ÷ 10 (2NA) 5 ÷ 3 3 ÷ 4 (1NA)
Urine log10 JCPyV load (range)§ 6.05 (3.20–7.61) 6.45 (3.20–6.82) 5.73 (4.11–7.53) 7.19 (4.61–7.61)
25th–75th percentile 4.80–6.82 5.73–6.73 4.14–5.72 5.90–7.40
PBMCs JCPyV+/JCPyV− 0 ÷ 32 (2NA) 0 ÷ 17 (1NA) 0 ÷ 8 0 ÷ 7 (1NA)
PBMCs log10 JCPyV load (range)§ / / / /
T12* Plasma JCPyV+/JCPyV− 1 ÷ 31 (2NA) 1 ÷ 16 (1NA) 0 ÷ 8 0 ÷ 7 (1NA) 0.821
Plasma log10 JCPyV load (range)§ 3.86 3.86 / /
Urine JCPyV+/JCPyV− 13 ÷ 18 (3NA) 6 ÷ 11 (1NA) 4 ÷ 3 (1NA) 3 ÷ 4 (1NA)
Urine log10 JCPyV load (range)§ 6.24 (2.87–8.80) 6.10 (3.60–8.80) 6.41 (4.84–8.48) 6.24 (2.87–8.30)
25th–75th percentile 4.84–6.76 4.34–6.47 5.76–7.19 4.56–7.27
PBMCs JCPyV+/JCPyV− 2 ÷ 30 (2NA) 1 ÷ 16 (1NA) 0 ÷ 8 1 ÷ 6 (1NA)
PBMCs log10 JCPyV load (range)§ 3.37 (3.35–3.39) 3.39 / 3.35
T18* Plasma JCPyV+/JCPyV− 12 ÷ 20 (2NA) 6÷10 (2NA) 3 ÷ 5 3 ÷ 5 0.707
Plasma log10 JCPyV load (range)§ 4.05 (3.83–4.98) 4.01 (3.83–4.32) 4.24 (3.96–4.77) 4.28 (3.95–4.98)
25th–75th percentile 3.96–4.29 3.91–4.06 4.10–4.51 4.12–4.63
Urine JCPyV+/JCPyV- 25÷7 (2NA) 12÷4 (2NA) 6 ÷ 2 7 ÷ 1
Urine log10 JCPyV load (range)§ 4.99 (2.55–8.29) 4.64 (2.55–8.29) 5.52 (3.06–6.99) 4.80 (3.55–7.28)
25th–75th percentile 3.86–6.43 3.83–6.28 4.29–6.33 4.51–7.01
PBMCs JCPyV+/JCPyV− 21 ÷ 11 (2NA) 10÷6 (2NA) 6 ÷ 2 5 ÷ 3
PBMCs log10 JCPyV load (range)§ 3.10 (2.06–3.77) 3.05 (2.06–3.77) 3.23 (2.85–3.76) 3.21 (2.83–3.74)
25th–75th percentile 2.95–3.39 2.95–3.12 2.95–3.39 2.96–3.39
p-value viruria 0.290 0.707 0.428
CIRDs, chronic inflammatory rheumatic diseases; PsA, psoriatic arthritis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; NA, sample not available.
*Times of follow up: baseline (T0) and 3, 6, 12, and 18 months (T3, T6, T12, and T18).
§JCPyV loads values were expressed as median (range) of log10 genome equivalent (gEq)/mL in urine and in plasma, and as median (range) log10 gEq/106 cells in PBMCs.
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FIGURE 1 | JCPyV urine loads vs. the corresponding plasma viral loads in CIRDs patients during the 18 month follow-up study. The values of JCPyV
viruria for each patient at the different time-points were reported on the x-axis whereas the corresponding viremia values on the y-axis. All JCPyV loads values were
expressed as median of log10 genome equivalent (gEq)/mL in urine and in plasma. Viremia was mainly associated to viruria during the entire follow-up.
Regarding the binding sites present in this rearranged
sequence, the TATA box and the binding site for Tst-1, required
for JCPyV replication and transcription of early and late
genes, respectively, were both well conserved within the box
A (Figure 3B). About the multiple duplication of box C, it
enhances the binding site for the cyclic AMP (cAMP) response
element (CRE), a protein that up-modulates JCPyV expression
in cells, and for NF-1, responsible for the JCPyV neurotropism
(Figure 3B). In addition, the binding sites for the cellular factors
NF-1, p53, and AP-1, involved in early viral transcription and in
neurotropism of the virus, are present within the box F, although
a single point mutation occurred into the NF-1 binding site
(Figure 3B).
Finally, an additional specific PCR was undertaken in order
to characterize the viral genotypes circulating within our CIRDs
cohort. Results showed a prevalence of the European genotypes
1A, 1B, and 4, followed by the Eurasian genotype 2B and the
Asian type 2E. In particular, genotypes 1A and 1B were identified
in 7 patients (1A in 4 PsA and 3 RA; 1B in 4 PsA, 2 RA, and 1 AS),
type 4 in 5 patients (3 PsA and 1 RA), whereas types 2B and 2E
were detected in a patient affected by PsA and in a patient with
AS, respectively (data not shown).
DISCUSSION
Biologic therapies have successfully been introduced into
the treatment of several inflammatory rheumatic diseases in
particular, monoclonal antibodies or fusion proteins targeting
TNF-α are widely used for the treatment of CIRDs patients
refractory to conventional immune-suppressive medications.
Nevertheless, treatments with biological drugs are associated with
an increased susceptibility to viral infections including that by
JCPyV, the etiological agent of the demyelinating disease named
PML (Comar et al., 2013; Iacobaeus et al., 2013). The incidence
of PML in immune-mediated diseases has recently increased as a
consequence of an improved use of biologics and other potent
immune-modulatory medications (Berger, 2010). Few studies
are present in literature that demonstrate a real risk of PML
development in CIRDs patients whereas several researches have
focused on a possible correlation between JCPyV viremia and the
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FIGURE 2 | Comparison of JCPyV viruria and viremia detected in
CIRDs patients in a 18 month follow-up study. At T0, JCPyV DNA was
revealed in 47.1% urine with a median value of 6.73 log10 (gEq)/ml and in
11.8% plasma with a median value of 4.62 log10 (gEq)/ml. At T3, 39.4% of
urine and 15.2% of plasma resulted JCPyV positive with a median value of
6.41 log10 (gEq)/ml and of 4.83 log10 (gEq)/ml respectively. At T6, in 45.2%
urine (median value 6.05 log10 (gEq)/ml) and in 9.4% plasma (median value
3.87 log10 (gEq)/ml), JCPyV genome was found. At T12, JCPyV viruria was
found in 41.9% specimens with a median value of 6.24 log10 (gEq)/ml.
Conversely, JCPyV viremia was detected in a single PsA patient with a viral
load of 3.86 log10 (gEq)/ml. Finally, at T18, JCPyV viruria was detected in
78.1% of CIRDs patients with a median load value of 4.99 log10 (gEq)/ml,
whereas JCPyV viremia was revealed in 37.5% of samples (median value of
4.05 log10 (gEq)/ml). JCPyV viruria was significantly higher than JCPyV viremia
throughout the entire follow-up (p = 0.002). JCPyV load values are expressed
as log10 genome equivalent per milliliter (gEq/mL). T0: baseline; T3, T6, T12
and T18: 3, 6, 12, and 18 months of anti-TNF-α, therapy. *indicates the
highest viremia value detected in one patient.
biological therapy in patients with multiple sclerosis (MS) and
CD (Lavagna et al., 2007; Verbeeck et al., 2008; Bellizzi et al., 2011,
2013a,b; Bharat et al., 2012; Comar et al., 2013; Iacobaeus et al.,
2013; Tur et al., 2013; Frohman et al., 2014). Therefore, it could be
interesting to understand whether there is a correlation between
biologics administered for CIRDs and the opportunity that the
virus escapes from latency, replicates actively and spreads to the
brain causing PML. In fact, despite the limited range of species
and permissive cell types for viral replication, JCPyV is a very
successful pathogen because of it is able to tightly regulate its life
cycle in the infected host.
In this study, 34 patients affected by RA, AS and PsA were
screened to detect the presence of JCPyV in blood and in urine
samples in order to evaluate the risk of JCPyV dissemination to
the CNS under treatments with biologic agents and/or DMARDs
and GCs. Patients were dynamically enrolled and studied from
baseline, before first anti-TNF-α infusion, up to 18 months
after.
A persistent JCPyV viruria significantly higher than JCPyV
viremia was observed from baseline throughout the 18 month
follow-up (p = 0.002). It could be explained taking in account
that the concomitant use of conventional therapies (DMARDs
and GCs) and anti-TNF-α treatments, rather than a single
biologic, endorsed JCPyV replication in urinary compartment.
In fact, over the time, no difference was observed between
JCPyV-positive and JCPyV-negative patients treated with single
administration of biologics or co-administration of DMARDs
and/or GC (Table 5). Conversely, a previous study demonstrated
a positive correlation between the JCPyV DNA detection in the
urine and the number of biologics consecutively used for RA
treatment (Verheyen et al., 2015). However, it is possible to
hypothesize that the prolonged administration of biologic agents
over time had a causative role in the increasing number of
patients with JC viruria after 18months of anti-TNF-α treatment.
Considering that TNF-α cytokine plays an important role in host
defense, it is feasible that the use of anti-TNF-α agents endorse
JCV replication in the kidney. In fact, Q-PCR revealed that
viral replication occurred in the urinary tract at high copy levels
and that the virus could escape into the peripheral circulation
as demonstrated by the fact that JCPyV DNA was detected
with an increased frequency in plasma and PBMCs at T18. In
addition, the effect of an ongoing immunosuppression on the
JCPyV replication is confirmed by the striking number of urine
positive samples detected at T18. These data allow an intriguing
speculation: JCPyV might directly trigger joint inflammation.
Indeed, it is well-known that viral infections can directly act on
the immune system through the secretion of pro-inflammatory
cytokines or favoring the production of autoantibodies (Franssila
andHedman, 2006). Therefore, urine JCPyV loads not only could
be supported by inflammatory state but also could be continuous
due to this insult.
The hypothesis of a role of biologics in promoting viruria
is also sustained by the results of an our previous study, in
which we observed a significantly increased JC viruria in young
patients with Crohn’s disease treated with infliximab respect
to those receiving a standard therapy (Bellizzi et al., 2011).
Regarding viremia, it was mainly associated to viruria during
the entire follow-up (Figure 1). Although JC viremia seems to
be essential for the development of PML and it was detected
in 37.5% (12/32) of our patients at T18, its short temporality
precludes its usefulness in screening or diagnostic algorithms, as
already demonstrated by other Authors in comparable studies
(Rinaldi et al., 2010; Bellizzi et al., 2015; Verheyen et al.,
2015). Hence, monitoring urine JCPyV replication is a good,
non-invasive method to check viral pathogenic potential. In
conclusion, results evidenced how viral replication and spreading
could be cumulatively influenced by the use of various immune-
suppressants, including biologics, rather than by a specific
medications, also considering their sequential administration
in the treatment refractory patients. However, due to the low
number of patients analyzed in this study, how cumulative effect
of various immunosuppressive agents really influence JCPyV
pathogenesis, need further validation. Therefore, the cohort of
studied subjects is being expanded.
In JCPyV DNA positive patients, NCCR sequencing always
revealed the presence of archetype-like structures, according to
other Authors (Giannecchini et al., 2012; Verheyen et al., 2015),
except for a rearranged NCCR form detected in the plasma
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FIGURE 3 | Comparison of NCCR structural forms and rearranged NCCR II-R found in a plasma sample at T3. (A) Type I-S is 98 base-pair (bp) long and it
is composed of box A (25 bp), box C (55 bp), box E (18 bp) and F (69 bp). Type I-R has repeats of this 98 bp unit, with various deletions, as seen in the JCPyV
prototype Mad-1 (GenBank no: J02227), that have no box B and box D (Jensen and Major, 2001). In particular, the prototype Mad-1 was isolated from tissues of
patients with PML (Tan and Koralnik, 2010) and it was named on the hypothesis that the prototype results from a rearrangement of the archetype sequence (Comar
et al., 2013). Type II-S is identified as archetype CY and it is composed of A (25 bp), B (23 bp), C (55 bp), D (66 bp), E (18 bp), and F (69 bp) boxes. It was isolated by
Yogo et al. (1990). Each box contains binding sites for transcriptional cell factors involved in viral early and late transcription. These binding sites undergo to deletion
and enhancement process that could generate variants that could up-modulate viral expression in a specific anatomical site (Jensen and Major, 2001). (B) In (B), the
rearranged sequence found in plasma at T3 is reported. This rearrangement presents the entire boxes A and C followed by a rearranged box C, shortened sequences
of boxes D and E, a new duplication of box C (complete and rearranged), incomplete boxes D and E and finally the entire box F. Asterisks represent single nucleotide
point mutations or deletions. Italicized capital letters indicate mutated nucleotides. The TATA box is presented by TATA. Boxes division from A to F is also shown. The
main binding sites for transcriptional cell factors are also indicated and the corresponding nucleotides sequences are underlined. Finally, the nucleotides sequences for
the transcriptional factor Spi-B are also shown in higher font.
sample of a patient affected by PsA (Figure 3B). Interestingly, this
type II-R rearrangement resembles the viral variants isolated in
subjects who developed PML, and it is characterized by a marked
neurotropism (Agostini et al., 2001; Marzocchetti et al., 2007).
Indeed, it showed several repeats of the box C containing the CRE
element, a specific enhancer of JCPyV replication in glial cells
(Kumar et al., 1996). Moreover, it is noteworthy that this NCCR
structure presents a high-affinity binding site for the specific
hematopoietic transcriptional factor Spi-B. In fact, it has been
demonstrated that Spi-B protein actively binds its site present
on Mad-1, but not in the non-pathogenic II-S (CY) (Marshall
et al., 2010, 2012). Therefore, it is possible to hypothesize that
this neurovirulent variant could enter PBMCs, using them as a
carrier to disseminate in the bloodstream and to reach the brain
(Kumar et al., 1996). Furthermore, it is well-known that detecting
viral genome in cerebrospinal fluid lied on PML diagnosis,
however, its failure does not rule out the possibility that a patient
might have PML, particularly in the earlier stages (Mischitelli
et al., 2013). Hence, identifying in the blood a virus with
PML-associated NCCR rearrangements should alert clinicians,
favoring an individual management of the patient.
Finally, regarding JCPyV genotyping, VP1 sequencing
evidenced that genotype 1A, 1B, and 4 were the most prevalent,
although genotypes 2B and 2E were also found. Type 1
and type 4 are generally associated with Europeans and
European-Americans, whereas type 2B and 2E were typical
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of Asians and Eurasians and of Western Pacific populations,
respectively (Agostini et al., 2001). Interestingly, JCPyV subtype
2B found in PsA patient with the PML-associated NCCR
rearrangement in the blood, has been associated with increased
incidence of PML, while type 4 has been associated with lower
disease risk (Agostini et al., 2001). Moreover, type 1 and type
4 were found in urine of Italian patients affected by immune-
mediated diseases, suggesting a possible JCPyV genotype
selection in response to pressure by immunomodulatory drugs
(Zanotta et al., 2013).
Recently, observations of point mutations in the VP1 capsid
gene have also been shown to be associated with PML (Delbue
et al., 2009; Reid et al., 2011). Although VP1 gene is highly
polymorphic, mutations appear to be strongly patient-related and
they have been observed in virus characterized by rearranged
NCCR. Practically, their arising is only noted in a neuro
aggressive viral variant evolved by the non-pathogenic form,
according to cell alterations or global environment changes. In
summary, either VP1 mutations and NCCR rearrangements are
the most common viral alterations associated with PML (Delbue
et al., 2009; Reid et al., 2011).
In conclusion, since biological therapies are promising
for the treatment of immune-mediated disorders, little is
known about their contribution to the development of PML.
However, it is clear that PML has been identified as a
serious adverse event, hence it is interesting to clarify
how anti TNF-α agents act on JCPyV immune-surveillance
endorsing viral reactivation and dissemination. To date,
epidemiology of PML has been poorly characterized among
patients with rheumatic diseases due to little population-
based data existing. Therefore, this study contributes to enrich
literature insight on JCPyV biology in this cluster of patients,
considering that the involvement of JC virus in development
of adverse events in CIRDs is probably underestimated since
few studies have been done about. Thus, it is necessary
to carry on investigations in order to understand the real
impact of biologic and/or other immunosuppressive therapies
on JCPyV life cycle and to identify possible and specific viral
variants that, in CIRDs patients, could be related to increased
virulence.
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